Please assess the completion status of the following clinical trial:

Trial Title: Afatinib in Subjects With Kidney Dysfunction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Despite renal impairment (group 1 and 2) healthy males or females according to the investigators assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests.~* Glomerular filtration rate (GFR), estimated according to:~  -- MDRD (Modification of Diet in Renal Disease)-formula:~ * eGFR (estimated Glomerular Filtration Rate) \[ml/min/1.73m²\]= 175 x Serum Creatinine-1.154 x age-0.203 (if male)~ * eGFR\[ml/min/1.73m²\]= 175 x Serum Creatinine-1.154 x age-0.203 x 0.742 (if female)~ * 30 to 59 mL/min for moderate renal impairment group 1~ * 15 to 29 mL/min for severe renal impairment group 2~ * = 90 mL/min for healthy volunteers group 3~* Age =18 and =79 years~Exclusion criteria:~* Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance, e.g. repeated measurement of systolic blood pressure \< 90 mmHg (millimeter of mercury) or \> 140 mmHg, diastolic blood pressure \< 50 mmHg or \> 90 mmHg, repeated measurement of pulse rate \< 45 bpm (beats per minute) or \> 90 bpm.~* Any evidence of a clinically relevant concomitant disease.~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, dermatological or hormonal disorders.~* Relevant gastrointestinal tract surgery (except appendectomy).~* Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or neurological disorders.~* History of photosensitivity or recurrent rash.~* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Afatinib in moderate renal impaired (Type: EXPERIMENTAL): Single Dose Afatinib in moderate renal impaired subjects
- Afatinib in severe renal impaired (Type: EXPERIMENTAL): Single Dose Afatinib in severe renal impaired subjects
- Afatinib in healthy subjects (Type: OTHER): Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).